Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Synthetic heptapeptide

Selank

A synthetic heptapeptide consisting of tuftsin (TKPR) extended by Pro-Gly-Pro. No approved drug product exists in the United States.

Also listed as: TP-7, Selank acetate

Chemical identity

Compound class
Synthetic heptapeptide; tuftsin analogue
Sequence
TKPRPGP
Molecular formula
C33H57N11O9
Molecular weight
751.9 g/mol
CAS number
129954-34-3
PubChem CID
11765600
Research categories
Peptide fragments, Preclinical research compounds

United States regulatory status

No FDA-approved product

  • No approved drug product exists in Drugs@FDA.
  • Listed as “Selank acetate (TP-7)” on FDA's table of bulk substances nominated for compounding and withdrawn by the nominator.
  • FDA's published concerns include aggregation and immunogenicity risk, and state that the nomination lacked important information regarding safety issues.
  • Not named on the WADA 2026 Prohibited List.

Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.

Sources

  1. PubChem CID 11765600
  2. FDA — Certain bulk drug substances for use in compounding may present significant safety risks

Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built